Yanhui Wen1,2, Lifeng Zhou3, Yuqiu Li4, Zhengmin Li5, Weijun Deng6, Tao Zhang7. 1. Department of Otolaryngology, Guangzhou Overseas Chinese Hospital, Jinan University, No. 613 West Huangpu Avenue, Guangzhou, 610632, China. 2. Department of Otolaryngology, The Third People's Hospital of Dongguan, Dongguan, China. 3. Department of Otolaryngology, Guangzhou Women and Children's Hospital, Guangzhou, China. 4. Department of Imaging, The Third People's Hospital of Dongguan, Dongguan, China. 5. Department of Otolaryngology, Boai Hospital of Zhongshan, Zhongshan, China. 6. Department of General Surgery, The Third People's Hospital of Dongguan, Dongguan, China. 7. Department of Otolaryngology, Guangzhou Overseas Chinese Hospital, Jinan University, No. 613 West Huangpu Avenue, Guangzhou, 610632, China. zhangtaoent@sohu.com.
Abstract
OBJECTIVE: Increasing evidence suggests that leptin is upregulated during allergic reactions in the airway and related to the severity of disease in allergic rhinitis (AR). In this study, we aimed to investigate the expression of leptin during sublingual immunotherapy (SLIT) in AR patients. METHODS:Forty AR patients without obesity were recruited in this study. Twenty patients receivedhouse dust mite (HDM) allergen extract for SLIT and twenty patients receivedplacebo randomly. Protein expression of leptin in serum and nasal lavage was tested by enzyme-linked immuno sorbent assay (ELISA) 1 and 2 years after SLIT treatment, respectively. Peripheral blood mononuclear cells (PBMCs) and human nasal epithelial cell were prepared and stimulated by recombinant leptin after 24 months' SLIT treatment and the induction of Th2 cytokines (IL-4/IL-5/IL-13) were detected by ELISA. RESULTS:SLIT treatment decreased the expression of leptin protein in serum and nasal lavage significantly compared with placebo group 1 and 2 years after SLIT treatment. Nasal leptin level was correlated to decreased Th2 response (IL-4/IL-5/IL-13) and enhanced Treg (IL-10/TGF-beat) response after 2 years' SLIT. We also found that SLIT decreased the ability of leptin in promoting Th2 cytokines expression by PBMCs and human nasal epithelial cell after 2 years' SLIT treatment. CONCLUSION: Changes of leptin expression in serum and nasal lavage may be correlated with Th2/Treg regulation during SLIT. Our results suggested that leptin served as an important biomarker during SLIT.
RCT Entities:
OBJECTIVE: Increasing evidence suggests that leptin is upregulated during allergic reactions in the airway and related to the severity of disease in allergic rhinitis (AR). In this study, we aimed to investigate the expression of leptin during sublingual immunotherapy (SLIT) in AR patients. METHODS: Forty AR patients without obesity were recruited in this study. Twenty patients received house dust mite (HDM) allergen extract for SLIT and twenty patients received placebo randomly. Protein expression of leptin in serum and nasal lavage was tested by enzyme-linked immuno sorbent assay (ELISA) 1 and 2 years after SLIT treatment, respectively. Peripheral blood mononuclear cells (PBMCs) and human nasal epithelial cell were prepared and stimulated by recombinant leptin after 24 months' SLIT treatment and the induction of Th2 cytokines (IL-4/IL-5/IL-13) were detected by ELISA. RESULTS: SLIT treatment decreased the expression of leptin protein in serum and nasal lavage significantly compared with placebo group 1 and 2 years after SLIT treatment. Nasal leptin level was correlated to decreased Th2 response (IL-4/IL-5/IL-13) and enhanced Treg (IL-10/TGF-beat) response after 2 years' SLIT. We also found that SLIT decreased the ability of leptin in promoting Th2 cytokines expression by PBMCs and human nasal epithelial cell after 2 years' SLIT treatment. CONCLUSION: Changes of leptin expression in serum and nasal lavage may be correlated with Th2/Treg regulation during SLIT. Our results suggested that leptin served as an important biomarker during SLIT.
Authors: Giorgio Ciprandi; Mara De Amici; Mariangela Tosca; Simone Negrini; Giuseppe Murdaca; Gian Luigi Marseglia Journal: Int Immunopharmacol Date: 2009-06-02 Impact factor: 4.932
Authors: Jan L Brozek; Jean Bousquet; Carlos E Baena-Cagnani; Sergio Bonini; G Walter Canonica; Thomas B Casale; Roy Gerth van Wijk; Ken Ohta; Torsten Zuberbier; Holger J Schünemann Journal: J Allergy Clin Immunol Date: 2010-09 Impact factor: 10.793